Objectives: Integrase strand transfer inhibitors (INSTIs) are the latest class of antiretroviral drugs that prevent the integration of proviral DNA into the host genome. The aim of this study was to describe, for the first time, INSTI resistance mutations observed in Croatian HIV-infected patients. 
INTRODUCTION
Croatia is a country with a centralized system of clinical care where all patients living with human immunodeficiency type 1 (HIV-1) infection are treated and monitored at the University Hospital for Infectious Diseases "Dr. Fran Mihaljevic" (UHID) in Zagreb. 1 Additionally, surveillance of HIV resistance to antiretroviral drugs (ART) has also been centralized at UHID since 2006.
2 ART suppresses HIV-1 replication to undetectable levels and enables immunological reconstitution in treated patients. 3 Currently, there are six distinct classes of ART that can be classified based on their molecular mechanism and resistance profile: nucleoside-analogue reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), integrase inhibitors (INSTI), fusion inhibitors, and CCR5 antagonist. Firstline ART consists of three or more antiretroviral drugs, usually two NRTIs in combination with one integrase inhibitor (recommended by the International AIDS Society-USA Guidelines, IAS-USA) or 3 INSTIs with boosted PI (Department of Health and Human Services Guidelines, DHHS). 4, 5 INSTIs are the most recently approved class of ART that exhibit exceptionally favorable characteristics of antiviral drugs including a high barrier to resistance (dolutegravir, bictegravir), good tolerability and high antiviral potency. Therefore, INSTIs quickly became an essential part of first-line ART regimens recommended by European AIDS Clinical Society (EACS) guidelines as well as by other professional societies within the field. 6, 7 INSTIs prevent the integration of proviral DNA into the host genome by inhibiting the strand-transfer activity of HIV-1 integrase (IN). 8 Currently, there are four INSTIs approved by the Food and Drugs Administration and the European Medicines Agency: raltegravir (RAL), elvitegravir (EGV), dolutegravir (DTG) and bictegravir (BIC). As of 2015, RAL, EVG and DTG are the INSTIs available in Croatia. Despite being highly effective in the treatment of HIV, resistance mutations occur in patients treated with the first generation of INSTIs (RAL and EGV), while data on primary resistance to these drugs (in previously untreated patients) are scarce.
9, 10 The appearance of major resistance mutations accompanied by further accumulation of secondary resistance mutations leads to the development of clinically significant resistance. 11, 12 Resistance to RAL has been extensively studied in the Benchmark trial in which the N155H, Q148H/K/R and Y143R pathways were identified. 13 Cross resistance between RAL and EVG has been described, and they are known to have a low genetic barrier which leads to the development of resistance with a single mutation. 14, 15 Reduced susceptibility to RAL is associated with at least 3 distinctive genetic pathways that are defined by a signature mutation Y143R/H/C, Q148H/K/R or N155H and one or more additional mutations (13) . Major resistance mutations for EVG include T66I, E92Q, Q148H/K/R, and N155H. 14, 15 Several mutations are required in HIV integrase to confer high-level resistance to DTG. Dolutegravir has a higher genetic barrier to resistance than elvitegravir and raltegravir, but Q148H/K/R mutation in combination with other additional mutations could reduce its long-term potency. 16 The R263K mutation was the first mutation rarely found selected at time of virological failure in patients failing a first-line dolutegravir-based treatment. 17 Current guidelines (DHHS, EACS, IAS-USA) recommend HIV-1 drug resistance testing for all HIV -1-infected patients prior to therapy initiation. Primary resistance testing to INSTIs as a part of routine clinical diagnostics is not currently recommended. 5, 7, 16 INSTI resistance testing has been introduced at the Department of Immunological and Molecular Diagnostics of UHID in 2016, and the majority of it is performed in patients with virological failure, as HIVinfected patients failing antiretroviral therapy should be carefully monitored. In clinical practice in Croatia, primary resistance to INSTIs is performed individually in ARV-naive patients. The aim of this study was to describe, for the first time, INSTI resistance mutations observed in Croatian HIV-infected patients.
MATERIAL AND METHODS

Study population
The present study was conducted between March 2016 and September 2018 and included 22 samples: 4 from ARV-naive and 18 from HIV-experienced patients failing therapy. Clinical and laboratory characteristics of the patients are presented in Table 1 . The data used in this study was extracted from the Database of the Croatian Reference center for HIV/AIDS that contains information on all HIV-infected patients from Croatia. In the study period, some patients were tested more than once, and for 5 patients both primary and secondary resistance testing was available. 
Antiretroviral resistance testing
Resistance to antiretroviral drugs in HIV-infected patients was performed by population-based sequencing of genes coding for enzymes that are the molecular targets of drugs. Isolation of total viral RNA from the plasma of HIV-infected patients as well as amplification of targeted genes were performed by using ViroSeq HIV-1 Genotyping System according to the manufacturer's instructions (Applied Biosystems, USA). 
RESULTS
INSTI resistance mutations were found only in samples of ARV-experienced patients (n=5). Mutations Q148R, N155H and E92Q were detected as major resistance mutations associated with RAL and EVG. Possible resistance to DTG was detected in one sample (mutation Q148R). The overall prevalence of INSTI resistance mutations in ARV-experienced patients was 27.8% (5/18) ( Table 2) . Furthermore, treatment status of these five patients at resistance testing were tenofovir/emtricitabin+raltegravir (patients 1, 2, 4 and 5), and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (patient 3). 
DISCUSSION
The results of this study have shown, for the first time, the prevalence and patterns of INSTI resistance mutations observed in HIV-1 infected Croatian patients. The results of this study also emphasize that naturally occurring mutations or substitutions conferring resistance to INSTIs are rare. The European SPREAD HIV resistance surveillance program published the results of a multicenter, crosssectional study in which the prevalence of INSTI resistance was evaluated by population sequencing of the integrase gene to determine whether spontaneously generated INSTI-resistant mutants could be circulating as minority species. 18 No signature INSTI mutations were detected, whereas integrase substitutions were found in 14.3% individuals. These results showed that no INSTI resistant variants were circulating in Europe before the introduction of INSTIs in clinical practice in 2007. 18 On the other hand, polymorphisms that could contribute to INSTI resistance were frequent. 18 There is limited number of studies analyzing transmitted drug resistance (in previously untreated patients) to INSTIs. Recent studies show very low prevalence of major resistance mutations (ranging between 0%-0.33%) in Austria, Veneto region of Italy, part of Canada, several African countries and USA. Accessory mutations were found in 0.66% to 8.5% of patients. [19] [20] [21] [22] [23] Performing integrase genotyping before initiating INSTI therapy is not required, but resistance testing in individuals failing INSTI therapy is clinically warranted. In this study, major RAL and EVG resistance mutations (Q148R, N155H, E92Q) rates were 27.8% in ARV-experienced patients. These are the first cases of patients experiencing virological Virological failure occurs frequently in routine clinical practice and is associated with accumulation of mutations leading to increasing levels of drug resistance. 25 Drug resistance reduces therapeutic options and the results of this study emphasize the importance of selecting the appropriate therapy when managing ARV-experienced patients by taking into account resistance testing results. Due to the high genetic barrier to resistance, second generation INSTIs (e.g. DVG or BIC) are viable treatment options for ART-experienced patients failing therapy. This concept is also supported by the results of our study showing possible resistance to DVG in only one patient. In conclusion, the results of this study emphasize the need for continuous surveillance of INSTI resistance in patients experiencing virological failure to antiretroviral treatment in Croatia.
